vTv Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Hypoglycemia remains common and burdensome despite CGM and AID, with survey data indicating clinically meaningful burdens across T1D populations. CATT1 is testing whether cadisegliatin can reduce hypoglycemia by 30% without sacrificing HbA1c; top-line results are expected mid-2027.
-
Cadisegliatin, a liver-selective glucokinase activator, is advancing through phase III trials for type 1 diabetes, aiming to reduce hypoglycemia and improve glycemic control. Enrollment for the pivotal CATT1 trial is on track, with top-line data expected in 2027 and sufficient funding secured.
-
The meeting established a quorum and proceeded with votes on director elections, auditor ratification, and executive compensation. All director nominees were elected, Ernst & Young was ratified as auditor, but the advisory vote on executive compensation did not pass.
-
CADI, a first-in-class oral adjunctive therapy for Type 1 diabetes, is in phase III with enrollment set to complete in Q3 and top-line data expected 7–8 months later. The therapy targets a major unmet need, has FDA Breakthrough Therapy status, and is supported by strong safety and efficacy data.
-
Cadisegliatin, a first-in-class oral adjunctive therapy for type 1 diabetes, is in phase III with top-line CATT1 data expected by year-end. The drug has shown significant reductions in hypoglycemia and A1C, with a strong safety profile and FDA breakthrough designation, addressing a major unmet need.